PetVivo Sets Fiscal First Quarter 2025 Conference Call for Wednesday, August 14 at 5:00 p.m. ET
August 08 2024 - 10:25AM
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical
company delivering innovative therapeutic medical devices for
equines and companion animals, will hold a conference call on
Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss
results for the fiscal first quarter ended June 30, 2024. The
financial results will be issued in a press release prior to the
call.
PetVivo management will host the presentation,
followed by a question-and-answer period.
Date: Wednesday, August 14, 2024Time: 5:00 p.m.
Eastern time (2:00 p.m. Pacific time)Toll-free dial-in number:
1-253-215-8782Conference ID: 85913290613Passcode: 187583Webcast
(live and replay): here
A replay of the webcast will be available
through the same link following the conference call.
The conference call webcast is also available
via a link in the Investors section of the company’s website at
petvivo.com/investors.
If you require any assistance connecting to the
call, please contact CMA at 1-949-432-7566.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a
biomedical device company focused on the manufacturing,
commercialization and licensing of innovative medical devices and
therapeutics for companion animals. The company is pursuing a
strategy of developing and commercializing human therapies for the
treatment of companion animals in capital and time efficient ways.
A key component of this strategy is an accelerated timeline to
revenues for veterinary medical devices that can enter the market
much earlier than more stringently regulated human pharmaceuticals
and biologics.
PetVivo has developed a robust pipeline of
products for the medical treatment of animals and people, with a
portfolio of 21 patents that protect the company's biomaterials,
products, production processes and methods of use. The company’s
commercially launched flagship product, Spryng™ with OsteoCushion™
Technology, is a veterinarian-administered, intra-articular
injectable designed for the management of lameness and other joint
related afflictions, including osteoarthritis, in cats, dogs and
horses.
For more information about PetVivo and its
revolutionary Spryng with OsteoCushion Technology, email
info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its
Investor Relations website as a means of disclosing material
nonpublic information and for complying with its disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the company’s Investor Relations website, in addition to
following the company’s press releases, SEC filings, public
conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo
Holdings, Inc. (the “Company”) may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Forward-looking statements include all statements
that do not relate solely to historical or current facts, including
without limitation the Company’s proposed development and
commercial timelines, and can be identified by the use of words
such as “may,” “will,” “expect,” “project,” “estimate,”
“anticipate,” “plan,” “believe,” “potential,” “should,” “continue”
or the negative versions of those words or other comparable words.
Forward-looking statements are not guarantees of future actions or
performance. These forward-looking statements are based on
information currently available to the Company and its current
plans or expectations and are subject to a number of uncertainties
and risks that could significantly affect current plans. Risks
concerning the Company’s business are described in detail in the
Company’s Annual Report on Form 10-K for the year ended March 31,
2024 and other periodic and current reports filed with the
Securities and Exchange Commission. The Company is under no
obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise. Company
ContactJohn Lai, CEOPetVivo Holdings, Inc.Email ContactTel
(952) 405-6216
Investor ContactRonald Both or Grant StudeCMA
Investor RelationsTel (949) 432-7566Email contact
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Nov 2024 to Dec 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Dec 2023 to Dec 2024